Fibroblast growth factor 23 and its role in bone diseases

References

• Beaubrun, A. C., R. D. Kilpatrick, J. K. Freburger, B. D. Bradbury, L. Wang, and M. A. Brookhart. 2013. “Temporal Trends in Fracture Rates and Postdischarge Outcomes among Hemodialysis Patients.” Journal of the American Society of Nephrology 24 (9): 1461–1469. https://doi.org/10.1681/ASN.2012090916
   PubMed Web of Science ®Google Scholar
• Bihari, C., D. Lal, M. Thakur, S. Sukriti, D. Mathur, A. G. Patil, L. Anand, et al. 2018. “Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis Are Associated with Hepatic Osteodystrophy.” Hepatology Communications 2 (9): 1095–1110. https://doi.org/10.1002/hep4.1234
   PubMed Web of Science ®Google Scholar
• Bilha, S. C., A. Bilha, M.-C. Ungureanu, A. Matei, A. Florescu, C. Preda, A. Covic, et al. 2020. “FGF23 Beyond the Kidney: A New Bone Mass Regulator in the General Population.” Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme [Hormone and Metabolic Research] 52 (5): 298–304. https://doi.org/10.1055/a-1151-2342
   PubMed Web of Science ®Google Scholar
• Bover, J., P. Urena-Torres, M. Cozzolino, M. Rodriguez-Garcia, and C. Gomez-Alonso. 2021. “The Non-Invasive Diagnosis of Bone Disorders in CKD.” Calcified Tissue International 108 (4): 512–527. https://doi.org/10.1007/s00223-020-00781-5
   PubMed Web of Science ®Google Scholar
• Cannata-Andía, J. B., B. Martín-Carro, J. Martín-Vírgala, J. Rodríguez-Carrio, J. J. Bande-Fernández, C. Alonso-Montes, N. Carrillo-López, et al. 2021. “Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.” Calcified Tissue International 108 (4): 410–422. https://doi.org/10.1007/s00223-020-00777-1
   PubMed Web of Science ®Google Scholar
• Carrillo-López, N., S. Panizo, C. Alonso-Montes, P. Román-García, I. Rodríguez, C. Martínez-Salgado, A. S. Dusso, et al. 2016. “Direct Inhibition of Osteoblastic Wnt Pathway by Fibroblast Growth Factor 23 Contributes to Bone Loss in Chronic Kidney Disease.” Kidney International 90 (1): 77–89. https://doi.org/10.1016/j.kint.2016.01.024
   PubMed Web of Science ®Google Scholar
• Celik, E., S. Guzel, R. Abali, A. Y. Guzelant, E. Celik Guzel, and V. Kucukyalcin. 2013. “The Relationship between Fibroblast Growth Factor 23 and Osteoporosis in Postmenopausal Women.” Minerva Medical 104 (5): 497–504.
   PubMed Web of Science ®Google Scholar
• Choksi, P., K. J. Jepsen, and G. A. Clines. 2018. “The Challenges of Diagnosing Osteoporosis and the Limitations of Currently Available Tools.” Clinical Diabetes and Endocrinology 4 (1): 12. https://doi.org/10.1186/s40842-018-0062-7
   PubMedGoogle Scholar
• Choy, M.-H. V., R. M.-Y. Wong, M.-C. Li, B. Y. Wang, X. D. Liu, W. Lee, J. C.-Y. Cheng, et al. 2020. “Can We Enhance Osteoporotic Metaphyseal Fracture Healing through Enhancing Ultrastructural and Functional Changes of Osteocytes in Cortical Bone with Low-Magnitude High-Frequency Vibration?” FASEB Journal 34 (3): 4234–4252. https://doi.org/10.1096/fj.201901595R
   PubMed Web of Science ®Google Scholar
• Consortium, A. 2000. “Autosomal Dominant Hypophosphataemic Rickets is Associated with Mutations in FGF23.” Nature Genetics 26 (3): 345–348.
   PubMed Web of Science ®Google Scholar
• Coulson, J., L. Bagley, Y. Barnouin, S. Bradburn, G. Butler-Browne, H. Gapeyeva, J.-Y. Hogrel, et al. 2017. “Circulating Levels of Dickkopf-1, Osteoprotegerin and Sclerostin Are Higher in Old Compared with Young Men and Women and Positively Associated with Whole-Body Bone Mineral Density in Older Adults.” Osteoporosis International 28 (9): 2683–2689. https://doi.org/10.1007/s00198-017-4104-2
   PubMed Web of Science ®Google Scholar
• Desbiens, L. C., A. Sidibe, R. V. Ung, and F. Mac-Way. 2022. “FGF23-Klotho Axis and Fractures in Patients Without and With Early CKD: A Case-Cohort Analysis of CARTaGENE.” The Journal of Clinical Endocrinology and Metabolism 107 (6): e2502–e12. https://doi.org/10.1210/clinem/dgac071
   PubMed Web of Science ®Google Scholar
• Ehnert, S., R. H. Aspera-Werz, M. Ruoss, S. Dooley, J. G. Hengstler, and S. Nadalin. 2019. “Hepatic Osteodystrophy-Molecular Mechanisms Proposed to Favor Its Development.” International Journal of Molecular Sciences. 20 (10): 2555.
   Web of Science ®Google Scholar
• Elder, C. J., and N. J. Bishop. 2014. “Rickets.” Lancet 383 (9929): 1665–1676. https://doi.org/10.1016/S0140-6736(13)61650-5
   PubMed Web of Science ®Google Scholar
• Endo, I., S. Fukumoto, K. Ozono, N. Namba, H. Tanaka, D. Inoue, M. Minagawa, et al. 2008. “Clinical Usefulness of Measurement of Fibroblast Growth Factor 23 (FGF23) in Hypophosphatemic Patients: proposal of Diagnostic Criteria Using FGF23 Measurement.” Bone 42 (6): 1235–1239. https://doi.org/10.1016/j.bone.2008.02.014
   PubMed Web of Science ®Google Scholar
• Erben, R. G. 2018. “Physiological Actions of Fibroblast Growth Factor-23.” Frontiers in Endocrinology 9: 267. https://doi.org/10.3389/fendo.2018.00267
   PubMed Web of Science ®Google Scholar
• Evenepoel, P., J. Bover, and P. Urena Torres. 2016. “Parathyroid Hormone Metabolism and Signaling in Health and Chronic Kidney Disease.” Kidney International 90 (6): 1184–1190. https://doi.org/10.1016/j.kint.2016.06.041
   PubMed Web of Science ®Google Scholar
• Evenepoel, P., J. Cunningham, S. Ferrari, M. Haarhaus, M. K. Javaid, M.-H. Lafage-Proust, D. Prieto-Alhambra, et al. 2021. “European Consensus Statement on the Diagnosis and Management of Osteoporosis in Chronic Kidney Disease Stages G4-G5D.” Nephrology, Dialysis, Transplantation 36 (1): 42–59. https://doi.org/10.1093/ndt/gfaa192
   PubMed Web of Science ®Google Scholar
• Florenzano, P., I. R. Hartley, M. Jimenez, K. Roszko, R. I. Gafni, and M. T. Collins. 2021. “Tumor-Induced Osteomalacia.” Calcified Tissue International 108 (1): 128–142. https://doi.org/10.1007/s00223-020-00691-6
   PubMed Web of Science ®Google Scholar
• Fonseca, H., D. Moreira-Goncalves, H. J. Coriolano, and J. A. Duarte. 2014. “Bone Quality: The Determinants of Bone Strength and Fragility.” Sports Medicine 44 (1): 37–53. https://doi.org/10.1007/s40279-013-0100-7
   PubMed Web of Science ®Google Scholar
• Friedman, A. W. 2006. “Important Determinants of Bone Strength: Beyond Bone Mineral Density.” Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 12 (2): 70–77. https://doi.org/10.1097/01.rhu.0000208612.33819.8c
   PubMed Web of Science ®Google Scholar
• Guo, Y. C., and Q. Yuan. 2015. “Fibroblast Growth Factor 23 and Bone Mineralisation.” International Journal of Oral Science 7 (1): 8–13. https://doi.org/10.1038/ijos.2015.1
   PubMed Web of Science ®Google Scholar
• Han, W., X. J. Bai, L. L. Han, X. F. Sun, and X. M. Chen. 2019. “The Relationship between Serum Fibroblast Growth Factor 23, Klotho, and Lumbar Spine Bone Mineral Density in Northern Chinese Postmenopausal Women.” Menopause 26 (5): 546–553. https://doi.org/10.1097/GME.0000000000001276
   PubMed Web of Science ®Google Scholar
• Hanusch, B., M. Prediger, S. P. Tuck, J. Walker, R. McNally, and H. K. Datta. 2021. “Bone Turnover Markers as Determinants of Bone Density and Fracture in Men with Distal Forearm Fractures: The Pathogenesis Examined in the Mr F Study.” Osteoporosis International 32 (11): 2267–2277. https://doi.org/10.1007/s00198-021-06001-6
   PubMed Web of Science ®Google Scholar
• Hidalgo, D. F., B. Boonpheng, S. Sikandar, L. Nasr, and J. Hidalgo. 2020. “Chronic Liver Disease and the Risk of Osteoporotic Fractures: A Meta-Analysis.” Cureus 12 (9): e10483. https://doi.org/10.7759/cureus.10483
   PubMed Web of Science ®Google Scholar
• Hsu, C. Y., L. R. Chen, and K. H. Chen. 2020. “Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.” International Journal of Molecular Sciences. 21 (18): 6846.
   Web of Science ®Google Scholar
• Imel, E. A., Z. Liu, M. Coffman, D. Acton, R. Mehta, and M. J. Econs. 2020. “Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets.” Journal of Bone and Mineral Research 35 (2): 231–238. https://doi.org/10.1002/jbmr.3878
   PubMed Web of Science ®Google Scholar
• Imel, E. A., Z. Liu, A. K. McQueen, D. Acton, A. Acton, L. R. Padgett, M. Peacock, et al. 2016. “Serum Fibroblast Growth Factor 23, Serum Iron and Bone Mineral Density in Premenopausal Women.” Bone 86: 98–105. https://doi.org/10.1016/j.bone.2016.03.005
   PubMed Web of Science ®Google Scholar
• Isakova, T., X. Cai, J. Lee, R. Katz, J. A. Cauley, L. F. Fried, A. N. Hoofnagle, et al. 2016. “Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.” Journal of Bone and Mineral Research 31 (4): 742–748. https://doi.org/10.1002/jbmr.2750
   PubMed Web of Science ®Google Scholar
• Jamal, S. A., S. L. West, and T. L. Nickolas. 2014. “The Clinical Utility of FRAX to Discriminate Fracture Status in Men and Women with Chronic Kidney Disease.” Osteoporosis International 25 (1): 71–76. https://doi.org/10.1007/s00198-013-2524-1
   PubMed Web of Science ®Google Scholar
• Kanaan, N., K. Claes, J.-P. Devogelaer, D. Vanderschueren, G. Depresseux, E. Goffin, and P. Evenepoel. 2010. “Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss.” Clinical Journal of the American Society of Nephrology 5 (10): 1887–1892. https://doi.org/10.2215/CJN.00950110
   PubMed Web of Science ®Google Scholar
• Kanbay, M., M. Vervloet, M. Cozzolino, D. Siriopol, A. Covic, D. Goldsmith, Y. Solak, et al. 2017. “Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury.” Calcified Tissue International 100 (3): 217–228. https://doi.org/10.1007/s00223-016-0206-7
   PubMed Web of Science ®Google Scholar
• Kanda, E., M. Yoshida, and S. Sasaki. 2012. “Applicability of Fibroblast Growth Factor 23 for Evaluation of Risk of Vertebral Fracture and Chronic Kidney Disease-Mineral Bone Disease in Elderly Chronic Kidney Disease Patients.” BMC Nephrology 13 (1): 122. https://doi.org/10.1186/1471-2369-13-122
   PubMedGoogle Scholar
• Kazama, J. J. 2017. “Chronic Kidney Disease and Fragility Fracture.” Clinical and Experimental Nephrology 21 (Suppl 1): 46–52. https://doi.org/10.1007/s10157-016-1368-3
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009. “KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).” Kidney International. Supplement (113): S1–S130.
   Google Scholar
• Kinoshita, Y., and S. Fukumoto. 2018. “X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.” Endocrine Reviews 39 (3): 274–291. https://doi.org/10.1210/er.2017-00220
   PubMed Web of Science ®Google Scholar
• Kristjansdottir, H. L., Mellström, D., Johansson, P., Karlsson, M., Vandenput, L., Lorentzon, M., Herlitz, H., Ohlsson, C., Lerner, U. H., and Lewerin, C. 2022. “Anemia is Associated with Increased Risk of Non-Vertebral Osteoporotic Fractures in Elderly Men: The Mros Sweden Cohort.” Archives of Osteoporosis 17 (1): 85. https://doi.org/10.1007/s11657-022-01130-9.
   PubMed Web of Science ®Google Scholar
• Lane, N. E., Parimi, N., Corr, M., Yao, W., Cauley, J. A., Nielson, C. M., Ix, J. H., Kado, D., and Orwoll, E. 2013. “Association of Serum Fibroblast Growth Factor 23 (FGF23) AND Incident Fractures in Older Men: The Osteoporotic Fractures in Men (Mros) Study.” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research 28 (11): 2325–2332. https://doi.org/10.1002/jbmr.1985
   PubMed Web of Science ®Google Scholar
• Linglart, A., E. A. Imel, M. P. Whyte, A. A. Portale, W. Högler, A. M. Boot, R. Padidela, et al. 2022. “Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.” The Journal of Clinical Endocrinology and Metabolism 107 (3): 813–824. https://doi.org/10.1210/clinem/dgab729
   PubMed Web of Science ®Google Scholar
• Linglart, A., M. Biosse-Duplan, K. Briot, C. Chaussain, L. Esterle, S. Guillaume-Czitrom, P. Kamenicky, et al. 2014. “Therapeutic Management of Hypophosphatemic Rickets from Infancy to Adulthood.” Endocrine Connections 3 (1): R13–30. https://doi.org/10.1530/EC-13-0103
   PubMed Web of Science ®Google Scholar
• Makitie, R. E., A. Kampe, A. Costantini, J. J. Alm, P. Magnusson, and O. Makitie. 2020. “Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23.” Journal of Bone and Mineral Research 35 (5): 901–912. https://doi.org/10.1002/jbmr.3959
   PubMed Web of Science ®Google Scholar
• Manghat, P., W. D. Fraser, A. S. Wierzbicki, I. Fogelman, D. J. Goldsmith, and G. Hampson. 2010. “Fibroblast Growth Factor-23 is Associated with C-Reactive Protein, Serum Phosphate and Bone Mineral Density in Chronic Kidney Disease.” Osteoporosis International 21 (11): 1853–1861. https://doi.org/10.1007/s00198-009-1142-4
   PubMed Web of Science ®Google Scholar
• Marsell, R., M. A. I. Mirza, H. Mallmin, M. Karlsson, D. Mellström, E. Orwoll, C. Ohlsson, et al. 2009. “Relation between Fibroblast Growth Factor-23, Body Weight and Bone Mineral Density in Elderly Men.” Osteoporosis International 20 (7): 1167–1173. https://doi.org/10.1007/s00198-008-0780-2
   PubMed Web of Science ®Google Scholar
• Mirna, M., A. Lauten, P. Jirak, R. Rezar, B. Wernly, V. Paar, T. K. Felder, et al. 2021. “Serum Levels of C-Terminal FGF23 (cFGF23) Are Associated with 1-Year-Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR).” European Journal of Internal Medicine 85: 98–107. https://doi.org/10.1016/j.ejim.2020.09.022
   PubMed Web of Science ®Google Scholar
• Mirza, M. A., M. K. Karlsson, D. Mellström, E. Orwoll, C. Ohlsson, O. Ljunggren, T. E. Larsson, et al. 2011. “Serum Fibroblast Growth Factor-23 (FGF-23) and Fracture Risk in Elderly Men.” Journal of Bone and Mineral Research 26 (4): 857–864. https://doi.org/10.1002/jbmr.263
   PubMed Web of Science ®Google Scholar
• Monegal, A., M. Navasa, P. Peris, J. Colmenero, A. Cuervo, A. Muxí, L. Gifre, et al. 2013. “Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?” Calcified Tissue International 93 (6): 571–576. https://doi.org/10.1007/s00223-013-9797-4
   PubMed Web of Science ®Google Scholar
• Murali, S. K., P. Roschger, U. Zeitz, K. Klaushofer, O. Andrukhova, and R. G. Erben. 2016. “FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner.” Journal of Bone and Mineral Research 31 (1): 129–142. https://doi.org/10.1002/jbmr.2606
   PubMed Web of Science ®Google Scholar
• Olauson, H., K. Lindberg, R. Amin, T. Sato, T. Jia, R. Goetz, M. Mohammadi, et al. 2013. “Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion.” PLOS Genetics 9 (12): e1003975. https://doi.org/10.1371/journal.pgen.1003975
   PubMed Web of Science ®Google Scholar
• Paul, J., K. E. Cherian, N. Kapoor, and T. V. Paul. 2019. “Treating Osteoporosis: A near Miss in an Unusual Case of FGF-23 Mediated Bone Loss.” BMJ Case Reports 12 (3): e228375. https://doi.org/10.1136/bcr-2018-228375
   PubMedGoogle Scholar
• Pereira, R. C., H. Jűppner, C. E. Azucena-Serrano, O. Yadin, I. B. Salusky, and K. Wesseling-Perry. 2018. “Patterns of FGF-23, DMP1, and MEPE Expression in Patients with Chronic Kidney Disease.” Bone 108 (6): 210–211. https://doi.org/10.1016/j.bone.2017.12.019
   PubMedGoogle Scholar
• Prié, D., A. Forand, C. Francoz, C. Elie, I. Cohen, M. Courbebaisse, D. Eladari, D. Lebrec, F. Durand, and G. Friedlander. 2013. “Plasma Fibroblast Growth Factor 23 Concentration is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List.” PLOS One 8 (6): e66182. https://doi.org/10.1371/journal.pone.0066182
   PubMed Web of Science ®Google Scholar
• Quintero-Platt, G., E. González-Reimers, M. Rodríguez-Gaspar, C. Martín-González, O. Pérez-Hernández, L. Romero-Acevedo, E. Espelosín-Ortega, M. J. d. l. Vega-Prieto, and F. Santolaria-Fernández. 2017. “Alpha Klotho and Fibroblast Growth Factor-23 Among Alcoholics.” Alcohol and Alcoholism 52 (5): 542–549. https://doi.org/10.1093/alcalc/agx041
   PubMed Web of Science ®Google Scholar
• Ribeiro, A. L., F. Mendes, E. Carias, F. Rato, N. Santos, P. L. Neves, A. P. Silva, et al. 2020. “FGF23-Klotho Axis as Predictive Factors of Fractures in Type 2 Diabetics with Early Chronic Kidney Disease.” Journal of Diabetes and Its Complications 34 (1): 107476. https://doi.org/10.1016/j.jdiacomp.2019.107476
   PubMed Web of Science ®Google Scholar
• Richter, B., and C. Faul. 2018. “FGF23 Actions on Target Tissues-With and Without Klotho.” Frontiers in Endocrinology 9: 189. https://doi.org/10.3389/fendo.2018.00189
   PubMed Web of Science ®Google Scholar
• Rupp, T., S. Butscheidt, E. Vettorazzi, R. Oheim, F. Barvencik, M. Amling, T. Rolvien, et al. 2019. “High FGF23 Levels Are Associated with Impaired Trabecular Bone Microarchitecture in Patients with Osteoporosis.” Osteoporosis International 30 (8): 1655–1662. https://doi.org/10.1007/s00198-019-04996-7
   PubMed Web of Science ®Google Scholar
• Sato, H., J. J. Kazama, A. Murasawa, H. Otani, A. Abe, S. Ito, H. Ishikawa, et al. 2016. “Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis.” Internal Medicine 55 (2): 121–126. https://doi.org/10.2169/internalmedicine.55.5507
   PubMed Web of Science ®Google Scholar
• Sirikul, W., N. Siri-Angkul, N. Chattipakorn, and S. C. Chattipakorn. 2022. “Fibroblast Growth Factor 23 and Osteoporosis: Evidence from Bench to Bedside.” International Journal of Molecular Sciences. 23 (5): 2500.
   PubMed Web of Science ®Google Scholar
• Sitara, D., S. Kim, M. S. Razzaque, C. Bergwitz, T. Taguchi, C. Schüler, R. G. Erben, et al. 2008. “Genetic Evidence of Serum Phosphate-Independent Functions of FGF-23 on Bone.” PLOS Genetics 4 (8): e1000154. https://doi.org/10.1371/journal.pgen.1000154
   PubMed Web of Science ®Google Scholar
• Slouma, M., T. Aissaoui, M. Abbes, A. Bahlous, L. Laadhar, W. Smaoui, I. Gharsallah, et al. 2021. “New Markers of Bone Fragility in Hemodialysis Patients: A Monocentric Study.” Journal of Clinical Densitometry 24 (1): 22–27. https://doi.org/10.1016/j.jocd.2020.11.002
   PubMed Web of Science ®Google Scholar
• Smith, E. R., M. M. Cai, L. P. McMahon, and S. G. Holt. 2012. “Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements.” The Journal of Clinical Endocrinology and Metabolism 97 (9): 3357–3365. https://doi.org/10.1210/jc.2012-1811
   PubMed Web of Science ®Google Scholar
• Urena Torres, P., G. Friedlander, M. C. de Vernejoul, C. Silve, and D. Prie. 2008. “Bone Mass Does Not Correlate with the Serum Fibroblast Growth Factor 23 in Hemodialysis Patients.” Kidney International 73 (1): 102–107. https://doi.org/10.1038/sj.ki.5002622
   PubMed Web of Science ®Google Scholar
• Wagner, J., K. D. Jhaveri, L. Rosen, S. Sunday, A. T. Mathew, and S. Fishbane. 2014. “Increased Bone Fractures among Elderly United States Hemodialysis Patients.” Nephrology, Dialysis, Transplantation 29 (1): 146–151. https://doi.org/10.1093/ndt/gft352
   PubMed Web of Science ®Google Scholar
• Wakasugi, M., J. J. Kazama, M. Taniguchi, A. Wada, K. Iseki, Y. Tsubakihara, I. Narita, et al. 2013. “Increased Risk of Hip Fracture among Japanese Hemodialysis Patients.” Journal of Bone and Mineral Metabolism 31 (3): 315–321. https://doi.org/10.1007/s00774-012-0411-z
   PubMed Web of Science ®Google Scholar
• Wang, H., Y. Yoshiko, R. Yamamoto, T. Minamizaki, K. Kozai, K. Tanne, J. E. Aubin, et al. 2008. “Overexpression of Fibroblast Growth Factor 23 Suppresses Osteoblast Differentiation and Matrix Mineralization in Vitro.” Journal of Bone and Mineral Research 23 (6): 939–948. https://doi.org/10.1359/jbmr.080220
   PubMed Web of Science ®Google Scholar
• Xu, L., L. Zhang, H. Zhang, Z. Yang, L. Qi, Y. Wang, S. Ren, et al. 2018. “The Participation of Fibroblast Growth Factor 23 (FGF23) in the Progression of Osteoporosis via JAK/STAT Pathway.” Journal of Cellular Biochemistry 119 (5): 3819–3828. https://doi.org/10.1002/jcb.26332
   PubMed Web of Science ®Google Scholar
• Yamamoto, S., and M. Fukagawa. 2017. “Uremic Toxicity and Bone in CKD.” Journal of Nephrology 30 (5): 623–627. https://doi.org/10.1007/s40620-017-0406-x
   PubMed Web of Science ®Google Scholar
• Yin, Q., H. Yang, L. Fang, Q. Wu, S. Gao, Y. Wu, L. Zhou, et al. 2023. “Fibroblast Growth Factor 23 Regulates Hypoxia‑Induced Osteoblast Apoptosis through the Autophagy‑Signaling Pathway.” Molecular Medicine Reports 28 (5): 199. https://doi.org/10.3892/mmr.2023.13086
   Web of Science ®Google Scholar
• Yokomoto-Umakoshi, M., H. Umakoshi, T. Miyazawa, M. Ogata, R. Sakamoto, and Y. Ogawa. 2021. “Investigating the Causal Effect of Fibroblast Growth Factor 23 on Osteoporosis and Cardiometabolic Disorders: A Mendelian Randomization Study.” Bone 143: 115777. https://doi.org/10.1016/j.bone.2020.115777
   PubMed Web of Science ®Google Scholar
• Zheng, S., Y. Chen, Y. Zheng, Z. Zhou, and Z. Li. 2018. “Correlation of Serum Levels of Fibroblast Growth Factor 23 and Klotho Protein Levels with Bone Mineral Density in Maintenance Hemodialysis Patients.” European Journal of Medical Research 23 (1): 18. https://doi.org/10.1186/s40001-018-0315-z
   PubMedGoogle Scholar
• Zou, D., W. Wu, Y. He, S. Ma, and J. Gao. 2018. “The Role of Klotho in Chronic Kidney Disease.” BMC Nephrology 19 (1): 285. https://doi.org/10.1186/s12882-018-1094-z
   PubMedGoogle Scholar